Open an account

Neuphoria Therapeutics

NEUP · NASDAQ

$3.39+$0.08 (+2.42%)TodayMarket closed ·
Prev close $3.31

About NEUP

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Employees
8
Headquarters
Burlington, Massachusetts
Listed
Dec 21, 1999
Sector
Health Care
Industry
Biotechnology
Website
neuphoriatx.com

NEUP key statistics

Market cap
18.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
18.57K
Volume
20.81K
Open price
$3.31
High today
$3.40
Low today
$3.33
52 Week high
$17.19
52 Week low
$3.19

Neuphoria Therapeutics (NEUP) at a glance

As of Oct 20, 2026, Neuphoria Therapeutics (NEUP) shares are priced at $3.39, giving the company a market cap of 18.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.33 and $3.40. The current price is 1.8% above the day's low and 0.3% below its high.

Volume so far is 20.81K shares, in line with the average of 18.57K shares a day.

Over the past year Neuphoria Therapeutics has ranged from $3.19 to $17.19, and now sits 1% of the way up that range.

Neuphoria Therapeutics met or beat analyst EPS estimates in 2 of the last 5 quarters. In Q4 FY26 it reported -$0.95 per share against an estimate of -$0.5712.

The average analyst price target is $7.14, 110.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $7.14
Low
$7.07
Now
$3.39
High
$7.35

NEUP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 5 quarters, by 69.7% on average.

  1. Q4 FY25: reported -$5.79 per share against an estimate of -$2.12
  2. Q1 FY26: reported -$4.41 per share against an estimate of -$1.35
  3. Q2 FY26: reported -$0.77 per share against an estimate of -$1.49
  4. Q3 FY26: reported -$0.09 per share against an estimate of -$0.9894
  5. Q4 FY26: reported -$0.95 per share against an estimate of -$0.5712

NEUP news

  • Press releasePRNewswire

    Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM

  • Press releaseBusiness Wire

    NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

  • Caroline Ryan

    Deal Dispatch: GoPro Retains Houlihan Lokey In Strategic Review, Brookfield Buys World Freight Company, YesCare Corp. Bankruptcy

Similar companies

Companies in the same industry as Neuphoria Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.